 |
Photo courtesy of Yonhap News |
[Alpha Biz= Paul Lee] SEOUL, October 27, 2025 — Yuhan Corporation announced on Monday that it has terminated its licensing agreement with Ubix Therapeutics, which had granted Yuhan the global exclusive rights to develop and commercialize UBX-103, a targeted androgen receptor degrader (TARD) for the treatment of prostate cancer.
The deal, signed in July 2024, was originally valued at ₩150 billion (US$108 million), covering upfront, milestone, and royalty payments.
Yuhan confirmed in a regulatory filing that the termination has been executed in accordance with the contract terms and clarified the financial settlement:
“Ubix Therapeutics will not return the ₩5 billion (US$3.6 million) upfront payment previously received, and Yuhan has no further payment obligations under the agreement.”
The company did not disclose the specific reasons for the termination but indicated that the decision was made as part of an internal pipeline optimization and portfolio review process.
UBX-103, developed by Ubix Therapeutics, was a next-generation androgen receptor degrader intended for castration-resistant prostate cancer (CRPC). The compound had been undergoing preclinical optimization at the time of the licensing agreement.
Both companies stated that they would continue exploring independent development strategies in oncology and protein degradation therapeutics.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
